JP Morgan analyst Anupam Rama upgrades Solid Biosciences (NASDAQ:SLDB) from Underweight to Neutral.
Analyst Expectations for Kymera Therapeutics’s Future
Within the last quarter, Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…